Amer Zeidan/yalemedicine.org
May 23, 2025, 06:26
Amer Zeidan Reflects on Anticipation for VERONA Trial Results in High-Risk MDS
Amer Zeidan, Associate Professor of Medicine (Hematology) at Yale University, posted on X:
“The entire MDS is anxiously waiting for the results of the randomized Phase 3 VERONA trial of azacitidine + venetoclax versus azacitidine-+Placebo in patients with higher risk MDS with the primary endpoint of overall survival, what do you expect the results to be?”
Amer Zeidan invited responses on expectations for the VERONA trial results in higher-risk MDS patients. He offered four answer options: positive, negative, too close to guess, or I don’t manage MDS.
More posts about MDS on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32